Blog

Expression system selection plays a central role in determining the success of VHH antibody development. Factors such as expression yield, folding efficiency, post-translational modifications (PTMs), scalability, and cost all influence the suitability of a given system for research, diagnostic, or therapeutic use.

PEGS Europe2025 conference was held inLisbon, Portugal, fromNovember11to November13, 2025.The Proteinand Antibody Engineering Summithad focusedsessions onbispecifics,multispecifics, machine learning, and novel target engagement

Explore microfluidic screening for function-first antibody discovery. Identify active antibodies early using single-cell droplet technology and native IgG secretion.

The Society for Immunotherapy of Cancer (SITC) 2025 conference was held in National Harbor, Maryland, from November 5 to November 9, 2025. Forty years ago, breakthroughs in recombinant DNA, monoclonal antibody technology, and tumor immunology laid the groundwork for cancer research. At SITC, experts and emerging investigators across biotech, academia, government, and pharma come to advance immuno-oncology and improve patient outcomes.

Compare immunized, naïve and synthetic VHH libraries, their workflows, advantages and use cases to select ideal nanobody discovery strategy for your projects.

Biointron is proud to announce the launch of the Biointron Quarterly Travel Grant Program, a new initiative designed to empower early-career scientists in the antibody field to share their research with the world. The program reflects our ongoing commitment to accelerating discovery and supporting the next generation of innovators driving progress in antibody science.

Read a recap of the 16th World ADC San Diego 2025 conference that was held in San Diego, California, from November 3 to November 6, 2025!

Discover how immune, naïve and synthetic VHH libraries are built, biopanned and optimized for therapeutic, diagnostic, imaging and research use globally now.

Learn how a developability-first approach improves antibody discovery by addressing stability, manufacturability, and safety early in therapeutic development.

Learn how early antibody developability assessment improves candidate selection, reduces risk, and accelerates drug discovery. Explore Biointron solutions.

BioJapan 2025 was held in Yokohama, Japan, from October 8 to October 10, 2025. The exhibition highlighted advances across AI-accelerated R&D, CRO integration, and cross-border innovation partnerships.Popular topics included:Antibody & Biologics DiscoveryAI and Data in Clinical Re

Each year, the Nobel Prizes recognize breakthroughs that reshape our understanding of the natural world. The 2025 awards in Chemistry and Physiology or Medicine highlight discoveries that bridge fundamental science and real-world impact, from molecular materials that can breathe gases to immune mechanisms that prevent the body from attacking itself.